OncoCyte Corp expected to post a loss of 87 cents a share - Earnings Preview

Insight Molecular Diagnostics

04/08/2023 13:35

* OncoCyte Corp  OCX.OQ   OCX.O  is expected to show a fall
in
quarterly revenue when it reports  results on August 9. 
    * The Irvine California-based  company is expected to report
 a
82.5% decrease in revenue to $362.5 thousand from $2.07 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for OncoCyte Corp is
for a
loss of 87 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$7.5​, above​ its last closing price of $4.03. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -1.31       -1.70      0.40      Beat    123.5
 Dec. 31 2023              -1.88      -8.00     Missed  -324.6
 Sep. 30 2022  -2.28       -2.26      -1.60     Beat    29.1​
 Jun. 30 2022  -2.32       -2.39      -1.40     Beat    41.3
 ​​Mar.        -2.34       -2.40      -2.20     Beat    8.3
 31 2022                                                
 Dec. 31 2021  -2.80       -2.54      -2.40     Beat    5.6​
 Sep. 30 2021  -2.32       -2.32      -3.00     Missed  -29.3
 Jun. 30 2021  -1.90       -2.00      -2.40     Missed  -20
 This summary was machine generated August 4 at 12:35 GMT.  All
figures in US dollars  unless otherwise stated